Amisulpride: a broad spectrum of clinical indications Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
amisulpride, schizophrenia, atypical antipsychotics
Main Article Content
Abstract
Amisulpride is an atypical antipsychotic used to treat acute and chronic schizophrenia, especially with predominance of negative symptoms such as blunting affect, and emotional or social withdrawal. Amisulpride is a dopamine D2 and D3 receptor antagonist with both low-dose presynaptic and limbic selectivity. Because of that unique mechanism, amisulpride belongs to antipsychotics with the highest potency, more effective than most of other antipsychotics. Amisulpride is well-tolerable and acceptable by patients, with very low risk of discontinuation comparing to all other typical and atypical antipsychotics.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-962.
2. Kahn RS, Fleischhacker WW, Boter H et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
3. Boter H, Peuskens J, Libiger J et al; EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115(2-3): 97-103.
4. Storosum JG, Elferink AJ, van Zwieten BJ et al. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 2002; 28(2): 193-201.
5. Schoemaker H, Claustre Y, Fage D et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280(1): 83-97.
6. CHPL: Charakterystyka Produktu Leczniczego z dnia 07.05.2012.
7. Amore M, Jori MC; Amisert investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. International Clinical Psychopharmacology 2001; 16(6): 317-324.
8. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 1997; 43(2): 95-103.
9. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998; 48(1): 47-56.
10. Ravizza L; AMILONG investigators. Amisulpride in mediumterm treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. Journal of Psychopharmacology 1999; 13(3): 248-254.
11. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999; 39(1): 25-32.
12. Rocca P, Fonzoa V, Ravizzaa L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Aff Dis 2002; 70(3): 313-317.
13. Bogorni F, Moreira FF, Pimentel EM et al. Amisulpride Augmentation for Clozapine-Refractory Positive Symptoms: Additional Benefit in Reducing Hypersialorrhea. Case Rep Psychiatry 2015; 2015: 408179.
14. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24(1): 1-13.
15. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. Pharmacopsychiatry 2004; 37(1): 26-31.
16. Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research 2010; 121(1-3): 118-124.
17. Thomas P, Vieta E. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatric Disease and Treatment 2008; 4(3): 675-686.
18. Torta R, Berra C, Binaschi L, Borio R. Combination therapy with amisulpride and antidepressants: Clinical observations in case series of elderly patients with psychotic depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008; 32(5): 1227-1230.
19. Kranke P, Eberhart L, Motsch J et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. British Journal of Anaesthesia 2013; 111(6): 938-945.
20. Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the shortterm treatment of depressive and physical symptoms in cancer patient s during chemotherapies. Support Care Cancer 2007; 15(5): 539-546.
2. Kahn RS, Fleischhacker WW, Boter H et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
3. Boter H, Peuskens J, Libiger J et al; EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115(2-3): 97-103.
4. Storosum JG, Elferink AJ, van Zwieten BJ et al. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 2002; 28(2): 193-201.
5. Schoemaker H, Claustre Y, Fage D et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280(1): 83-97.
6. CHPL: Charakterystyka Produktu Leczniczego z dnia 07.05.2012.
7. Amore M, Jori MC; Amisert investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. International Clinical Psychopharmacology 2001; 16(6): 317-324.
8. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 1997; 43(2): 95-103.
9. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998; 48(1): 47-56.
10. Ravizza L; AMILONG investigators. Amisulpride in mediumterm treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. Journal of Psychopharmacology 1999; 13(3): 248-254.
11. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999; 39(1): 25-32.
12. Rocca P, Fonzoa V, Ravizzaa L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Aff Dis 2002; 70(3): 313-317.
13. Bogorni F, Moreira FF, Pimentel EM et al. Amisulpride Augmentation for Clozapine-Refractory Positive Symptoms: Additional Benefit in Reducing Hypersialorrhea. Case Rep Psychiatry 2015; 2015: 408179.
14. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24(1): 1-13.
15. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. Pharmacopsychiatry 2004; 37(1): 26-31.
16. Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research 2010; 121(1-3): 118-124.
17. Thomas P, Vieta E. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatric Disease and Treatment 2008; 4(3): 675-686.
18. Torta R, Berra C, Binaschi L, Borio R. Combination therapy with amisulpride and antidepressants: Clinical observations in case series of elderly patients with psychotic depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008; 32(5): 1227-1230.
19. Kranke P, Eberhart L, Motsch J et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. British Journal of Anaesthesia 2013; 111(6): 938-945.
20. Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the shortterm treatment of depressive and physical symptoms in cancer patient s during chemotherapies. Support Care Cancer 2007; 15(5): 539-546.